{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:01:45Z","timestamp":1785402105507,"version":"3.56.0"},"reference-count":101,"publisher":"Pivot Science Publications Corporation","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"award":["R01 CA269685"],"award-info":[{"award-number":["R01 CA269685"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Heterog Plast"],"abstract":"<jats:p>Gastric cancer is a lethal malignancy with highly variable clinical behavior, reflecting both inter-tumor diversity and marked heterogeneity within individual lesions. Large-scale genomics data (including TCGA and ACRG) has delineated recurring molecular subtypes, while expression- and immunohistochemistry-based schemes provide clinically practical surrogates. However, single-cell and spatial profiling reveal that most tumors comprise multiple malignant epithelial states alongside diverse cancer-associated fibroblast (CAF) and immune programs that vary spatially, evolve during progression, and are remodeled by therapy. The Hippo pathway effectors YAP and TAZ act as central integrators of oncogenic, inflammatory, and mechanical cues that coordinate these dynamic states. In gastric cancer, YAP\/TAZ activity is enriched in diffuse\/EMT-like and mesenchymal phenotypes, associates with peritoneal dissemination, and contributes to immune evasion and treatment resistance. Here, we link YAP\/TAZ activity to gastric cancer subtype heterogeneity and emphasize two interconnected dimensions: (i) cell heterogeneity, encompassing coexisting epithelial lineage states and CAF subsets within tumors; and (ii) cell plasticity, highlighting reversible transitions that enable invasion, metastasis, and drug resistance. Finally, we propose a framework of YAP\/TAZ-governed epithelial-stromal ecotypes and discuss implications for biomarkers and rational combination strategies incorporating Hippo-targeted agents with chemotherapy, stromal modulation, and immunotherapy.<\/jats:p>","DOI":"10.47248\/chp2603030008","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:30:17Z","timestamp":1783013417000},"source":"Crossref","is-referenced-by-count":0,"title":["Hippo-YAP\/TAZ signaling in gastric cancer: orchestrating epithelial-stromal heterogeneity, plasticity, and therapy resistance"],"prefix":"10.47248","author":[{"given":"Junsong","family":"Zhao","sequence":"first","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Balch","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Athavale","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Yao","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Ghelfi","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Torres","sequence":"additional","affiliation":[{"name":"Camden Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Hong","sequence":"additional","affiliation":[{"name":"Camden Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamin","family":"Morrison","sequence":"additional","affiliation":[{"name":"Camden Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Spitz","sequence":"additional","affiliation":[{"name":"Camden Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Generosa","family":"Grana","sequence":"additional","affiliation":[{"name":"Camden Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Song","sequence":"additional","affiliation":[{"name":"Coriell Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26871","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tThe Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.","DOI":"10.1038\/nature13480"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tCristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449-456.","DOI":"10.1038\/nm.3850"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tChia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016;27:763-769.","DOI":"10.1093\/annonc\/mdw040"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tSohn BH, Hwang JE, Jang HJ, Lee H-S. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project. Clin Cancer Res. 2017;23:4441-4449.","DOI":"10.1158\/1078-0432.CCR-16-2211"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tMa Y, Jiang C, Pan L, Zhou Y, Xia R, Liu Z, et al. Current development of molecular classifications of gastric cancer based on omics. Int J Oncol. 2024;64:48.","DOI":"10.3892\/ijo.2024.5677"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tOrtega A, Vera I, Diaz MP, Navarro C, Rojas M, Torres W, et al. The YAP\/TAZ signaling pathway in the tumor microenvironment and carcinogenesis: current knowledge and therapeutic promises. Int J Mol Sci. 2022;23:430.","DOI":"10.3390\/ijms23010430"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tYan Z, Liu Y, Yuan Y. The plasticity of epithelial cells and its potential in the induced differentiation of gastric cancer. Cell Death Discov. 2024;10:512.","DOI":"10.1038\/s41420-024-02275-x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tYun H, Dong F, Wei X, Yan X, Zhang R, Zhang X, et al. Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer. Oncol Rep. 2025;53:14.","DOI":"10.3892\/or.2024.8847"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tJia X, Li Z, Zhou R, Feng W, Yi L, Zhang H, et al. Single cell and bulk RNA sequencing identify tumour microenvironment subtypes and chemoresistance-related IGF1-positive cancer-associated fibroblasts in gastric cancer. Bba-mol Basis Dis. 2024;1870:167123.","DOI":"10.1016\/j.bbadis.2024.167123"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tThilakasiri P, Li J, Parkinson L. Mechanisms of cellular crosstalk in the gastric tumour ecosystem are mediated by YAP1 and STAT3. Life Sci Alliance. 2023;7:e202302411.","DOI":"10.26508\/lsa.202302411"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tMatsuoka T, Yashiro M. Molecular mechanisms for malignant progression of gastric cancer: tumour microenvironment and genetic alterations. Int J Mol Sci. 2024;25:11735.","DOI":"10.3390\/ijms252111735"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tLee JY, Hong M, Kim ST. Spatially distinct reprogramming of the tumor microenvironment in diffuse-type gastric cancer. Clin Cancer Res. 2021;27:6529-6543.","DOI":"10.1158\/1078-0432.CCR-21-0792"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tZhang C, Li J, Han Y. Immune landscape of gastric carcinoma tumour microenvironment. Front Immunol. 2021;12:651033.","DOI":"10.3389\/fimmu.2021.651033"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tCao Z, Yu J, Qin L. The Hippo signaling pathway in gastric cancer. Acta Biochim Biophys Sin. 2023;55:893-903.","DOI":"10.3724\/abbs.2023038"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tMessina B, Malagola M, Grizzi F. Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. Cell Death Dis. 2023;14:466.","DOI":"10.1038\/s41419-023-05568-8"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tLiu X, Wang Y, Chen B, Chan WN, Miu CW, Cheung AHK, et al. Targeting the Hippo pathway in gastric cancer and other malignancies in the digestive system: from bench to bedside. Biomedicines. 2022;10:2512.","DOI":"10.3390\/biomedicines10102512"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tCao Z, Hou Y, Zhao Z, Zhang H, Tian L, Zhang Y, et al. Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity. J Biol Chem. 2024;300:107311.","DOI":"10.1016\/j.jbc.2024.107311"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tKang W, Tong JH, Chan AW, Lee T-L, Lung RWM, Leung PPS, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17:2130-2139.","DOI":"10.1158\/1078-0432.CCR-10-2467"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tBencivenga M, Torroni L, Dal Cero M, Quinzii A, Zecchetto C, Merz V, et al. YAP activation is associated with a worse prognosis of poorly cohesive gastric cancer. J Pers Med. 2023;13:1294.","DOI":"10.3390\/jpm13091294"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tZhang P, Liu D, Zang Y, Wang J, Liu Z, Zhu J, et al. USP12 facilitates gastric cancer progression via stabilizing YAP. Cell Death Discov. 2024;10:174.","DOI":"10.1038\/s41420-024-01943-2"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tFranklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023;23:512-525.","DOI":"10.1038\/s41568-023-00579-1"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tRiquelme I, Saavedra K, Espinoza JA, Weber H, Garcia P, Nervi B, et al. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget. 2015;6:24750-24779.","DOI":"10.18632\/oncotarget.4990"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tLee SH, Lee D, Choi J, Oh HJ, Ham I-H, Ryu D, et al. Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages. Gut. 2025;74:714-727.","DOI":"10.1136\/gutjnl-2024-332901"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tOh SC, Sohn BH, Cheong JH, Kim S-B, Lee JE, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9:1777.","DOI":"10.1038\/s41467-018-04179-8"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tKim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449-1458.","DOI":"10.1038\/s41591-018-0101-z"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tJeong YS, Eun YG, Lee SH, Kang S-H, Yim SY, Kim EH, et al. Clinically conserved genomic subtypes of gastric adenocarcinoma. Mol Cancer. 2023;22:147.","DOI":"10.1186\/s12943-023-01796-w"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tDaun T, Nienhold R, Paasinen-Sohns A, Frank A, Sachs M, Zlobec I, et al. Combined simplified molecular classification of gastric adenocarcinoma, enhanced by lymph node status: an integrative approach. Cancers (Basel). 2021;13:3722.","DOI":"10.3390\/cancers13153722"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tKim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, et al. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016;7:44608-44620.","DOI":"10.18632\/oncotarget.10115"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tBirkman EM, Mansuri N, Kurki S, \u00c5lgars A, Lintunen M, Ristam\u00e4ki R. Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics. Virchows Arch. 2018;472:369-382.","DOI":"10.1007\/s00428-017-2240-x"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tGonzalez RS, Messing S, Tu X. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma. Hum Pathol. 2016;56:16-21.","DOI":"10.1016\/j.humpath.2016.06.003"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tTan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141:476-485.e1-11.","DOI":"10.1053\/j.gastro.2011.04.042"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tLei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554-565.","DOI":"10.1053\/j.gastro.2013.05.010"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tKumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12:670-691.","DOI":"10.1158\/2159-8290.CD-21-0683"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tWang R, Song S, Harada K, Amlashi FG, Badgwell B, Pizzi MP, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69:18-31.","DOI":"10.1136\/gutjnl-2018-318070"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tWang R, Dang M, Harada K, Han G, Wang F, Pizzi MP, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27:141-151.","DOI":"10.1038\/s41591-020-1125-8"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tLi X, Sun Z, Peng G, Xiao Y, Guo J, Wu B, et al. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in gastric cancer. Theranostics. 2022;12:620-638.","DOI":"10.7150\/thno.60540"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tFu M, Hu Y, Lan T, Guan K-L, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376.","DOI":"10.1038\/s41392-022-01191-9"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tCunningham R, Hansen CG. The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets. Clin Sci. 2022;136:197-222.","DOI":"10.1042\/CS20201474"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tZanconato F, Cordenonsi M, Piccolo S. YAP\/TAZ at the roots of cancer. Cancer Cell. 2016;29:783-803.","DOI":"10.1016\/j.ccell.2016.05.005"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tLuo J, Deng L, Zou H, Guo Y, Tong T, Huang M, et al. New insights into the ambivalent role of YAP\/TAZ in human cancers. J Exp Clin Cancer Res. 2023;42:130.","DOI":"10.1186\/s13046-023-02704-2"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tZhou T, Li X, Liu J, Hao J. The Hippo\/YAP signaling pathway: the driver of cancer metastasis. Cancer Biol Med. 2023;20:483-489.","DOI":"10.20892\/j.issn.2095-3941.2023.0164"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tWarren JS, Xiao Y, Lamar JM. YAP\/TAZ activation as a target for treating metastatic cancer. Cancers. 2018;10:115.","DOI":"10.3390\/cancers10040115"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tZou G, Huang Y, Zhang S, Ko KP, Kim B, Zhang J, et al. CDH1 loss promotes diffuse-type gastric cancer tumorigenesis via epigenetic reprogramming and immune evasion. J Exp Med. 2024, 221(4):e20230561.","DOI":"10.1084\/jem.20230561"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tBala R, Sharma A, Kumar S. Targeting the Hippo\/YAP pathway: a promising approach for cancer therapy and beyond. MedComm. 2025;6:e70338.","DOI":"10.1002\/mco2.70338"},{"key":"ref44","unstructured":"45.\tGhaboura N. Unraveling the Hippo pathway: YAP\/TAZ as central players in cancer metastasis and drug resistance. EXCLI J. 2025;24:612-637."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tKim J, Park C, Kim KH, Kim EH, Kim H, Woo JK, et al. Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. NPJ Precis Oncol. 2022;6:9.","DOI":"10.1038\/s41698-022-00251-1"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tSong S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014;74:4170-4182.","DOI":"10.1158\/0008-5472.CAN-13-3569"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tAjani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021;20:55-66.","DOI":"10.1136\/gutjnl-2019-319748"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tSong S, Xu Y, Huo L, Zhao S, Wang R, Li Y, et al. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res. 2021;40:207.","DOI":"10.1186\/s13046-021-02003-8"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tLamar JM, Stern P, Liu H, Schindler JW, Jiang Z-G, Hynes RO. The Hippo pathway target YAP promotes metastasis and chemoresistance. Proc Natl Acad Sci U S A. 2012;109:E2441-E2450.","DOI":"10.1073\/pnas.1212021109"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tChoi W, Kim J, Park J, Lee D-H, Hwang D, Kim J-H, et al. YAP\/TAZ initiates gastric tumorigenesis via upregulation of MYC. Cancer research. 2018;78(12):3306-3320.","DOI":"10.1158\/0008-5472.CAN-17-3487"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tHasegawa T, Sugihara T, Hoshino Y, Tarumoto R, Matsuki Y, Kanda T, et al. Photosensitizer verteporfin inhibits the growth of YAP\u2011 and TAZ\u2011dominant gastric cancer cells by suppressing the anti\u2011apoptotic protein Survivin in a light\u2011independent manner. Oncol Lett. 2021;22:12964.","DOI":"10.3892\/ol.2021.12964"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tCheng PSW, Zaccaria M, Biffi G. Functional heterogeneity of fibroblasts in primary tumours and metastases. Trends Cancer. 2025;11:135-153.","DOI":"10.1016\/j.trecan.2024.11.005"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tLuo H, Xia X, Huang L-B, An H, Cao M, Kim GD, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumour microenvironment. Nat Commun. 2022;13:6619.","DOI":"10.1038\/s41467-022-34395-2"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tXu Y, Li W, Lin S, Liu B, Wu P, Li L. Fibroblast diversity and plasticity in the tumour microenvironment: roles in immunity and relevant therapies. Cell Commun Signal. 2023;21:234.","DOI":"10.1186\/s12964-023-01204-2"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tSong S, Honjo S, Jin J, Chang S-S, Scott AW, et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015;21(11):2580-2590.","DOI":"10.1158\/1078-0432.CCR-14-2191"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tLi F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, et al. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4\/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019;25(7):2264-2277.","DOI":"10.1158\/1078-0432.CCR-18-1029"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tWang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. 2023;41(8):1407-1426.e9.","DOI":"10.1016\/j.ccell.2023.06.005"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tKang B, Camps J, Fan B, Jiang H, Ibrahim MM, Hu X, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol. 2022;23:265.","DOI":"10.1186\/s13059-022-02828-2"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tWang H, Yang L, Chen W, Li K, Xu M, Peng X, et al. High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy. Front Immunol. 2024;15:1446613.","DOI":"10.3389\/fimmu.2024.1446613"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tZhang X, Ren B, Liu B, Wang R, Li S, Zhao Y, et al. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer. J Transl Med. 2025;23:344.","DOI":"10.1186\/s12967-025-06376-8"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tZhao Z, Xiong S, Guo E, Huang H, Zhang Y. PDPN-positive, LTBP1-positive cancer-associated fibroblasts induce a liver pre-metastatic niche in gastric cancer via PDPN-YAP-LTBP1 and CCL11-CCR3 axes. Cell Commun Signal. 2025;23:402.","DOI":"10.1186\/s12964-025-02379-6"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tQin Y, Wang F, Ni H, Liu Y, Yin Y, Zhou X, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12:3011-3023.","DOI":"10.7150\/jca.49707"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tGalbo PM, Jr., Zang Y, Zheng D. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021;27:2636-2647.","DOI":"10.1158\/1078-0432.CCR-20-4226"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tSun H, Wang X, Wang X, Xu M, Sheng W. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death Dis. 2022;13:874.","DOI":"10.1038\/s41419-022-05320-8"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tYamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K. The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment. Cancer Sci. 2023;114:16-24.","DOI":"10.1111\/cas.15609"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tVenning FA, Zornhagen KW, Wullkopf L, Sjolund J, Rodriguez-Cupello C, Kjellman P, et al. Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. J Exp Clin Cancer Res. 2021;40:175.","DOI":"10.1186\/s13046-021-01944-4"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tWright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers (Basel). 2023;15:1899.","DOI":"10.3390\/cancers15061899"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tCalvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637-646.","DOI":"10.1038\/ncb2756"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tOzmen E, Demir TD, Ozcan G. Cancer-associated fibroblasts: protagonists of the tumor microenvironment in gastric cancer. Front Mol Biosci. 2024;11:1340124.","DOI":"10.3389\/fmolb.2024.1340124"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tChen B, Tang H, Zheng X, Xie F, Yu P, Lyu Y, et al. Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer. Mol Cancer. 2025;24:282.","DOI":"10.1186\/s12943-025-02490-9"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tZhang X, Ren B, Liu B, Wang R, Li S, Zhao Y, et al. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer. J Transl Med. 2025;23:344.","DOI":"10.1186\/s12967-025-06376-8"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tWang H, Yang L, Chen W, Li K, Xu M, Peng X, et al. High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy. Front Immunol. 2024;15:1446613.","DOI":"10.3389\/fimmu.2024.1446613"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tYang D, Li T, Li Y. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322-1332.","DOI":"10.1038\/s12276-023-01013-0"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tXia Z, De Wever O. The plasticity of cancer-associated fibroblasts. Trends Cancer. 2025;11:770-789.","DOI":"10.1016\/j.trecan.2025.04.012"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tBiffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147-176.","DOI":"10.1152\/physrev.00048.2019"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tZhou D, Zheng L. Recent advances in cancer-associated fibroblasts: biomarkers, signaling pathways, and therapeutic opportunities. Chin Med J (Engl). 2024;137:638-650.","DOI":"10.1097\/CM9.0000000000003031"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tHarada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018;21:31-40.","DOI":"10.1007\/s10120-017-0760-3"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tYang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322-1332.","DOI":"10.1038\/s12276-023-01013-0"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tPiccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023;4:9-26.","DOI":"10.1038\/s43018-022-00473-z"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tGupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2019;24:65-78.","DOI":"10.1016\/j.stem.2018.11.011"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tZhao Z, Mak TK, Shi Y, Li K, Huo M, Zhang C, et al. Integrative analysis of cancer-associated fibroblast signature in gastric cancer. Heliyon. 2023;9:e19217.","DOI":"10.1016\/j.heliyon.2023.e19217"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tSteen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39(10):1422-1437.e10.","DOI":"10.1016\/j.ccell.2021.08.011"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\tDu F, Ju J, Zheng F, Gao S, Yuan P. The identification of novel prognostic and predictive biomarkers in breast cancer via the elucidation of tumor ecotypes using ecotyper. Cancer Innov. 2025;4(4):e70013.","DOI":"10.1002\/cai2.70013"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tWang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, et al. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Comm. 2025;16:9968.","DOI":"10.1038\/s41467-025-65016-3"},{"key":"ref85","unstructured":"86.\tWang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3\u03c3 sequestering YAP in the cytoplasm. Am J Cancer Res. 2015;6(1):27-37."},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.\tDash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, et al. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024;300(9):107615.","DOI":"10.1016\/j.jbc.2024.107615"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tYap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R, et al. YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial. Nat Med. 2025:1-10.","DOI":"10.1038\/s41591-025-04029-3"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tWei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP\u2010TEAD complex. Cancer science. 2017;108(3):478-487.","DOI":"10.1111\/cas.13138"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"90.\tFeng J, Gou J, Jia J, Yi T, Cui T, Li Z. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9: 5371-5381.","DOI":"10.2147\/OTT.S109979"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tSong S, Xie M, Scott AW, Jin J, Ma L, Dong X, et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther. 2018;17(2):443-454.","DOI":"10.1158\/1535-7163.MCT-17-0560"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tMorice S, Mullard M, Brion R, Dupuy M, Renault S, Tesfaye R, et al. The YAP\/TEAD axis as a new therapeutic target in osteosarcoma: effect of verteporfin and CA3 on primary tumor growth. Cancers. 2020;12(12):3847.","DOI":"10.3390\/cancers12123847"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93.\tHan S, Lim JY, Cho K, Lee HW, Park JY, Ro SW, et al. Anti-cancer effects of YAP inhibitor (CA3) in combination with sorafenib against hepatocellular carcinoma (HCC) in patient-derived multicellular tumor spheroid models (MCTS). Cancers. 2022;14(11):2733.","DOI":"10.3390\/cancers14112733"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tAlva\u2010Ruiz R, Watkins RD, Tomlinson JL, Yonkus JA, Abdelrahman AM, Conboy CB, et al. YAP\u2010TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS Open Bio. 2024;14(11):1873-1887.","DOI":"10.1002\/2211-5463.13901"},{"key":"ref94","unstructured":"95.\tKaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am. J. Cancer Res. 2020;10(12):4399-4415."},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tHagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nature Cancer. 2023;4(6):812-828.","DOI":"10.1038\/s43018-023-00577-0"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97.\tWu Y, Hou Y, Xu P, Deng Y, Liu K, Wang M, et al. The prognostic value of YAP1 on clinical outcomes in human cancers. Aging (Albany, NY). 2019;11(19):8681.","DOI":"10.18632\/aging.102358"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"98.\tEun Y-G, Lee D, Lee YC, Sohn BH, Kim EH, Yim SY, et al. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget. 2017;8(67):111130.","DOI":"10.18632\/oncotarget.22666"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"99.\tHarvey KF, Tang TT. Targeting the Hippo pathway in cancer. Nat Rev Drug Discov. 2025;24:852-869.","DOI":"10.1038\/s41573-025-01234-0"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100.\tSong S, Honjo S, Jin J, Chang S-S, Scott AW, Chen Q, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21(11):2580-2590.","DOI":"10.1158\/1078-0432.CCR-14-2191"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tElhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41(3):404-420.","DOI":"10.1016\/j.ccell.2023.01.010"}],"container-title":["Cancer Heterogeneity and Plasticity"],"original-title":[],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:33:09Z","timestamp":1783013589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pivotscipub.com\/chp\/3\/3\/0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":101,"URL":"https:\/\/doi.org\/10.47248\/chp2603030008","relation":{},"ISSN":["2818-7792"],"issn-type":[{"value":"2818-7792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"0008"}}